Contracts › 75A50124C00061

75A50124C00061: Partner Therapeutics: the Overall Objective of This Contract Is to Confirm Leukine Safety in Sepsis Patients, Inform Optimal Leukine Dosing, Explore Leukine Efficacy, As Well As Advance Development of Monocyte Human Leukocyte Antigen-Dr (MHLA-DR) As

Awarded to Partner Therapeutics, Inc. by Office of Assistant Secretary for Preparedness and Response.

$13.0Mobligated

$13.7Mpotential value

31 March 2028current end date

See modifications, all subcontractors and funding in FedSift →

Contract	75A50124C00061
Awardee	Partner Therapeutics, Inc.
Awarding agency	Office of Assistant Secretary for Preparedness and Response
Awarding office	BARDA - ASPR / DAAPPO / BARDA DCMA
NAICS	541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology)
PSC	AN13 Health R&D Services; Health Care Services; Experimental Development
Place of performance	MA
Offers received	100
Period of performance	30 September 2024 to 31 March 2028
Potential end	30 September 2028
Estimated recompete solicitation	~Q4 2027 (estimate, ~6 months before expiry)

Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.